Uppsala, January 4, 2023. The pharmaceutical company Dicot announces the contracting of reputable Clinical Trial Consultants AB (CTC) for conducting clinical phase 1 studies intended to start in mid-2023. The studies will take place at the contracted company's research clinic in Uppsala.
Dicot is developing a new potency drug with the aim to treat erectile dysfunction and premature ejaculation better than existing drugs. The company has earlier announced its intention to start clinical studies with the drug candidate LIB-01 in mid-2023.
As an important part of the preparations for starting clinical trials, Dicot has finalized the procurement process and selects CTC to conduct the phase 1 studies. CTC is a reputable CRO with a track record of over 400 completed studies for both small and large international pharmaceutical companies. CTC has five state-of-the-art clinical research units in Uppsala, Stockholm and Linköping. Dicot's phase 1 studies will take place at the clinical unit in Uppsala.
"CTC came out as the strongest candidate in our procurement process, in competition with several international companies. I'm convinced this will be a good collaboration built on high-level competence and great commitment from both parties. Our joint work starts already now in January," says Elin Trampe, CEO at Dicot.
"We are very excited about the opportunity to collaborate with a local innovative pharmaceutical company like Dicot, and together with them take their candidate LIB-01 into clinical trials for the first time", comments Anders Millerhovf, CEO at CTC.
For further information, please contact:
Elin Trampe, CEO
Tel: +46 739 80 14 08
Email: elin.trampe@dicot.se
About Dicot AB
Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at SEK 60 billion. Dicot's strategy is to develop LIB-01 under own auspices until phase 2a studies and thereafter in partnership with larger, established pharmaceutical companies, finance and develop LIB-01 further to a registered pharmaceutical on the world market.
Dicot is listed on Spotlight Stock Market and has approximately 3,300 shareholders. For more information, please visit www.dicot.se.
Press release: Uppsala, February 27, 2023. Dicot AB (publ) hereby publishes its year-end report for the period January - December 2022 and for the fourth quarter. The year-end report is available as an attached document and on the company's website www.dicot.se. Below is a summary of the report.
Fourth quarter 2022
- Net sales amounts to KSEK 0 (0)
- Earnings after financial items amounts to KSEK -8,604 (-8,408)
- Earnings per share amounts to SEK -0.06 (-0.10)
January - December 2022
- Net sales amounts to KSEK 0 (0)
- Earnings after financial items amounts to KSEK -31,756 (-27,175)
- Earnings per share amounts to SEK -0.26 (-0.42)
Press release: Uppsala, November 1, 2022. The correction is to inform that the previous press release regarding Dicot AB's (publ) interim report for January - September 2022 should not have been marked with the MAR label.
Press release: Uppsala, November 1, 2022. A summary of the Interim report January - September 2022, for Dicot AB (publ) is now available on the company website www.dicot.se.
Dicot reports that the preclinical toxicology studies that are now being conducted, so far show that the drug candidate LIB-01 has a good safety profile.
Press release: Uppsala, August 25, 2022. A summary of the Interim report January - June 2022, for Dicot AB (publ) is now available on the company website www.dicot.se.
Press release: Uppsala, June 29, 2022. Dicot AB is developing a new potency drug aiming at becoming the first choice of treatment. The company announces today that the newly developed oral formulation demonstrates good results in a recently conducted efficacy study.
Press release: Uppsala, June 17, 2022.
Dicot AB (publ) ("Dicot" or the "Company") announces the outcome regarding exercising of warrants of series TO 3. Holders of warrants exercised 34,202,814 warrants, corresponding to approximately 90 percent of the number of outstanding warrants, for subscription of 34,202,814 shares at a subscription price of SEK 0.29 per share. Through the exercise of the warrants, Dicot will receive approximately SEK 10 million before issue costs.
Press release: Uppsala, June 13, 2022. The company announces that members in the board and management are increasing their shareholding in the company.
Press release: Uppsala, May 29, 2022.
During the fourth quarter of 2021, Dicot AB (publ) (``Dicot`` or ``the Company``) conducted a rights issue of units, with one (1) unit consisting of three (3) new issued shares and three (3) free-of-charge warrants of series TO 3 (previously also named series 2021/2022). Those who subscribed for units during the subscription period between October 12, 2021, and October 27, 2021, therefore obtained three (3) additional warrants of series TO 3 per unit subscribed. Each warrant of series TO 3 entitles the holder to subscribe for one (1) new share in Dicot. The subscription price for subscription of shares using warrants will correspond to 70 percent of the average volume-weighted price of the Company's share according to Spotlight Stock market's official list during the period from May 16, 2022, up to and including May 27, 2022. However, the subscription price shall not be higher than 1.50 SEK or lower than 0.125 SEK (corresponding quota value of the Company's share). The average volume-weighted price of the Company's share during the measurement period amounted to approximately 0.41 SEK, hence, the subscription price has been set to 0.29 SEK per share.
Press release: Uppsala, May 6, 2022. A summary of the Interim report January - March 2022, for Dicot AB (publ) is now available on the company website www.dicot.se
First quarter 2022
- Net sales amounts to kSEK 0 (0)
- Earnings for the period amounts to kSEK -9,346 (-8,468)
- Earnings per share SEK -0.09 (-0.19)